Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs intravenous ondansetron to prevent postoperative nausea and vomiting
IRCT20250107064314N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ondansetron in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoint: Incidence of postoperative nausea and vomiting. Started Feb 2025; status: completed.
02
Drugs
ondansetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on IRCT20250107064314N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250107064314N1.